Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HuMax-CD20 in active rheumatoid arthritis after DMARD failure
2004-003771-37Phase 2Completed
- Sponsor
- Genmab
- Start
- Nov 2005
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in rheumatoid arthritis (RA) comparing HuMax-CD20 with Placebo (2 arms). Primary endpoint: Adverse events. Started Nov 2005; status: completed.
02
Drugs
ofatumumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2004-003771-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-003771-37.